Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug

Nature Communications

Volumn 6, Issue , 2015, Pages

  Marschallinger, Julia ^a   Schäffner, Iris ^b   Klein, Barbara ^a   Gelfert, Renate ^a   Rivera, Francisco J ^a   Illes, Sebastian ^a   Grassner, Lukas ^a,c   Janssen, Maximilian ^a   Rotheneichner, Peter ^a   Schmuckermair, Claudia ^d   Coras, Roland ^e   Boccazzi, Marta ^f   Chishty, Mansoor ^g   Lagler, Florian B ^a   Renic, Marija ^h   Bauer, Hans Christian ^a   Singewald, Nicolas ^d   Blümcke, Ingmar ^e   Bogdahn, Ulrich ⁱ   Couillard Despres, Sebastien ^a   Lie, D Chichung ^b   Abbracchio, Maria P ^f   Aigner, Ludwig ^a   more..

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c BG Traumacenter Murnau eV Berufsgenossenschaftliche Unfallklinik Murnau   (Germany)

^d UNIVERSITY OF INNSBRUCK   (Austria)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f UNIVERSITY OF MILAN   (Italy)

^g Pharmidex   (United Kingdom)

^h UNIVERSITY OF ZAGREB   (Croatia)

ⁱ UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; BRAIN; COGNITION; DISABILITY; DISEASE TREATMENT; DRUG; GENE EXPRESSION; HISTOPATHOLOGY; LIFE EXPECTANCY; NEUROLOGY; RODENT;

ANIMALIA; RATTUS;

ANTIASTHMATIC AGENT; LEUKOTRIENE RECEPTOR;

ADULT; AGE; AGING; ANIMAL; BRAIN; COGNITION; CYTOLOGY; DRUG EFFECTS; FEMALE; FISCHER 344 RAT; GENETICS; HIPPOCAMPUS; HUMAN; MALE; MAZE TEST; METABOLISM; NERVE CELL; PHYSIOLOGY; RAT; YOUNG ADULT;

ADULT; AGE FACTORS; AGING; ANIMALS; ANTI-ASTHMATIC AGENTS; BRAIN; COGNITION; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; NEURONS; RATS; RATS, INBRED F344; RECEPTORS, LEUKOTRIENE; YOUNG ADULT;

EID: 84945922429     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9466     Document Type: Article

References (70)

1. Brown, R. C., Lockwood, A. H. & Sonawane, B. R. Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect. 113, 1250-1256 (2005).
2. Dilger, R. N. & Johnson, R. W. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J. Leukoc. Biol. 84, 932-939 (2008).
3. Sierra, A., Gottfried-Blackmore, A. C., McEwen, B. S. & Bulloch, K. Microglia derived from aging mice exhibit an altered inflammatory profile. Glia 55, 412-424 (2007).
4. Hefendehl, J. K. et al. Homeostatic and injury-induced microglia behavior in the aging brain. Aging Cell 13, 60-69 (2014).
5. Mosher, K. I. & Wyss-Coray, T. Microglial dysfunction in brain aging and Alzheimers disease. Biochem. Pharmacol. 88, 594-604 (2014).
6. Hart, A. D., Wyttenbach, A., Perry, V. H. & Teeling, J. L. Age related changes in microglial phenotype vary between CNS regions: grey versus white matter differences. Brain Behav. Immun. 26, 754-765 (2012).
7. Villeda, S. A. et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90-94 (2011).
8. Morrison, J. H. & Baxter, M. G. The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat. Rev. Neurosci. 13, 240-250 (2012).
9. Masliah, E., Mallory, M., Hansen, L., DeTeresa, R. & Terry, R. D. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 43, 192-197 (1993).
10. Bake, S. & Sohrabji, F. 17beta-estradiol differentially regulates blood-brain barrier permeability in young and aging female rats. Endocrinology 145, 5471-5475 (2004).
11. Heye, A. K., Culling, R. D., Valdes Hernandez, M. D., Thrippleton, M. J. & Wardlaw, J. M. Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. Neuroimage Clin. 6, 262-274 (2014).
12. Kuhn, H. G., Dickinson-Anson, H. & Gage, F. H. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J. Neurosci. 16, 2027-2033 (1996).
13. Spalding, K. L. et al. Dynamics of hippocampal neurogenesis in adult humans. Cell 153, 1219-1227 (2013).
14. Villeda, S. A. et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 20, 659-663 (2014).
15. Peters-Golden, M. Expanding roles for leukotrienes in airway inflammation. Curr. Allergy Asthma Rep. 8, 367-373 (2008).
16. Reiss, T. F. et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J. Allergy Clin. Immunol. 98, 528-534 (1996).
17. Kyritsis, N. et al. Acute inflammation initiates the regenerative response in the adult zebrafish brain. Science 338, 1353-1356 (2012).
18. Phillis, J. W., Horrocks, L. A. & Farooqui, A. A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Rev. 52, 201-243 (2006).
19. Farias, S., Frey, L. C., Murphy, R. C. & Heidenreich, K. A. Injury-related production of cysteinyl leukotrienes contributes to brain damage following experimental traumatic brain injury. J Neurotrauma 26, 1977-1986 (2009).
20. Tang, S. S. et al. Leukotriene D4 induces cognitive impairment through enhancement of CysLT(1) R-mediated amyloid-beta generation in mice. Neuropharmacology 65, 182-192 (2013).
21. Chinnici, C. M., Yao, Y. & Pratico, D. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol. Aging 28, 1457-1462 (2007).
22. Lecca, D. et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS ONE 3, e3579 (2008).
23. Zhang, X. Y. et al. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J. Pharmacol. Exp. Ther. 346, 328-341 (2013).
24. Saad, M. A., Abdelsalam, R. M., Kenawy, S. A. & Attia, A. S. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats. Neurochem. Res. 40, 139-150 (2015).
25. Lenz, Q. F. et al. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction. Neuroscience 277, 859-871 (2014).
26. Huber, C. et al. Inhibition of leukotriene receptors boosts neural progenitor proliferation. Cell Physiol. Biochem. 28, 793-804 (2011).
27. FDA, Montelukast. (Singulair, application number 20-829) (Pharmacology Review).
28. Kozlowski, C. & Weimer, R. M. An automated method to quantify microglia morphology and application to monitor activation state longitudinally in vivo. PLoS ONE 7, e31814 (2012).
29. da Silva, R. P. & Gordon, S. Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein. Biochem J 338, 687-694 (1999).
30. Bake, S., Friedman, J. A. & Sohrabji, F. Reproductive age-related changes in the blood brain barrier: expression of IgG and tight junction proteins. Microvasc. Res. 78, 413-424 (2009).
31. Kanak, D. J., Rose, G. M., Zaveri, H. P. & Patrylo, P. R. Altered network timing in the CA3-CA1 circuit of hippocampal slices from aged mice. PLoS ONE 8, e61364 (2013).
32. Maisel, M. et al. Transcription profiling of adult and fetal human neuroprogenitors identifies divergent paths to maintain the neuroprogenitor cell state. Stem Cells 25, 1231-1240 (2007).
33. Ren, H. et al. FoxO1 target Gpr17 activates AgRP neurons to regulate food intake. Cell 149, 1314-1326 (2012).
34. Gao, B., Vavricka, S. R., Meier, P. J. & Stieger, B. Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS. Pflugers Arch. 467, 1481-1493 (2014).
35. Liddelow, S. A. et al. Cellular specificity of the blood-CSF barrier for albumin transfer across the choroid plexus epithelium. PLoS ONE 9, e106592 (2014).
36. Kumar, A., Prakash, A., Pahwa, D. & Mishra, J. Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats. Pharmacol. Biochem. Behav. 103, 43-52 (2012).
37. Kalonia, H., Kumar, P., Kumar, A. & Nehru, B. Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-alpha level alterations in rats. Neuroscience 171, 284-299 (2010).
38. Lai, J. et al. Montelukast rescues primary neurons against Abeta1-42-induced toxicity through inhibiting CysLT1R-mediated NF-kappaB signaling. Neurochem. Int. 75, 26-31 (2014).
39. Yu, G. L. et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, doseand time-dependently protects against focal cerebral ischemia in mice. Pharmacology 73, 31-40 (2005).
40. Cavus, G. et al. Effects of montelukast and methylprednisolone on experimental spinal cord injury in rats. Eur. Rev. Med. Pharmacol. Sci. 18, 1770-1777 (2014).
41. Zhang, X. Y. et al. Regulation of rotenone-induced microglial activation by 5-lipoxygenase and cysteinyl leukotriene receptor 1. Brain Res. 1572, 59-71 (2014).
42. Corona, A. W., Fenn, A. M. & Godbout, J. P. Cognitive and behavioral consequences of impaired immunoregulation in aging. J. Neuroimmune Pharmacol. 7, 7-23 (2012).
43. Zheng, X. et al. Thinking outside the brain for cognitive improvement: is peripheral immunomodulation on the way? Neuropharmacology 96, 94-104 (2014).
44. Wang, L. et al. Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 187, 2336-2345 (2011).
45. Fabel, K. & Kempermann, G. Physical activity and the regulation of neurogenesis in the adult and aging brain. Neuromol. Med. 10, 59-66 (2008).
46. Drapeau, E. et al. Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis. Proc. Natl Acad. Sci. USA 100, 14385-14390 (2003).
47. Baruch, K. et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89-93 (2014).
48. Mosher, K. I. et al. Neural progenitor cells regulate microglia functions and activity. Nat. Neurosci. 15, 1485-1487 (2012).
49. Sierra, A. et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell 7, 483-495 (2010).
50. Kohman, R. A., Bhattacharya, T. K., Kilby, C., Bucko, P. & Rhodes, J. S. Effects of minocycline on spatial learning, hippocampal neurogenesis and microglia in aged and adult mice. Behav. Brain Res. 242, 17-24 (2013).
51. Paik, J. H. et al. FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell 5, 540-553 (2009).
52. Ceruti, S. et al. The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain 132, 2206-2218 (2009).
53. Firuzi, O., Zhuo, J., Chinnici, C. M., Wisniewski, T. & Pratico, D. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimers disease. FASEB J. 22, 1169-1178 (2008).
54. Ikonomovic, M. D., Abrahamson, E. E., Uz, T., Manev, H. & Dekosky, S. T. Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimers disease. J. Histochem. Cytochem. 56, 1065-1073 (2008).
55. Uz, T., Pesold, C., Longone, P. & Manev, H. Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J. 12, 439-449 (1998).
56. Yagami, T., Yamamoto, Y. & Kohma, H. Leukotriene receptor antagonists, LY293111 and ONO-1078, protect neurons from the sPLA2-IB-induced neuronal cell death independently of blocking their receptors. Neurochem. Int. 63, 163-171 (2013).
57. Coppi, E. et al. UDP-glucose enhances outward K() currents necessary for cell differentiation and stimulates cell migration by activating the GPR17 receptor in oligodendrocyte precursors. Glia 61, 1155-1171 (2013).
58. Sensi, C. et al. Oxysterols act as promiscuous ligands of class-A GPCRs: in silico molecular modeling and in vitro validation. Cell Signal 26, 2614-2620 (2014).
59. Qi, A. D., Harden, T. K. & Nicholas, R. A. Is GPR17 a P2Y/leukotriene receptor? examination of uracil nucleotides, nucleotide sugars, and cysteinyl leukotrienes as agonists of GPR17. J. Pharmacol. Exp. Ther. 347, 38-46 (2013).
60. Hennen, S. et al. Decoding signaling and function of the orphan G proteincoupled receptor GPR17 with a small-molecule agonist. Sci. Signal 6, ra93 (2013).
61. Cheng, F. et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput. Biol. 8, e1002503 (2012).
62. Kosaraju, J. et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimers disease. Neuropharmacology 72, 291-300 (2013).
63. Steinbrecher, A. et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J. Immunol. 166, 2041-2048 (2001).
64. Schrodl, F. et al. Rat choroidal pericytes as a target of the autonomic nervous system. Cell Tissue Res. 356, 1-8 (2014).
65. Paik, J. H. et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128, 309-323 (2007).
66. Chen, Y. et al. The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. Nat. Neurosci. 12, 1398-1406 (2009).
67. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001).
68. Blasi, E., Barluzzi, R., Bocchini, V., Mazzolla, R. & Bistoni, F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus J. Neuroimmunol. 27, 229-237 (1990).
69. Ehm, O. et al. RBPJkappa-dependent signaling is essential for long-term maintenance of neural stem cells in the adult hippocampus. J. Neurosci. 30, 13794-13807 (2010).
70. Nakae, J., Kitamura, T., Silver, D. L. & Accili, D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 108, 1359-1367 (2001).